Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

Martinez-Lopez, Joaquin, Blade, Joan, Mateos, María-Victoria, Grande, Carlos, Alegre, Adrián, García-Laraña, José, Sureda, Anna, de la Rubia, Javier, Conde, Eulogio, Martinez, Rafael, de Arriba, Felipe, Viguria, Maria C., Besalduch, Joan, Cabrera, Rafael, Gonzalez-San Miguel, José D., Guzman-Zamudio, José Luis, Gomez del Castillo, Maria Carmen, Moraleda, José Maria, García-Ruiz, Juan C., San Miguel, Jesús, Lahuerta, Juan José, for the GEM (Grupo Español de MM) and PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatía Maligna) Cooperative Study Groups · 2011 · Blood

Abstract

For establishing the true effect of different response categories in patients with multiple myeloma (MM) treated with autologous stem cell transplantation, we evaluated, after a median follow-up of 153 months, 344 patients with MM who received a transplant between 1989 and 1998. Overall survival (OS) at 12 years was 35% in complete response (CR) patients, 22% in near complete response (nCR), 16% in very good partial response (VGPR), and 16% in partial response (PR) groups. Significant differences in OS and progression-free survival were found between CR and nCR groups (P = .01 and P = .002, respectively), between CR and VGPR groups (P = .0001 and P = .003), or between CR and PR groups (P = .003 and P = < 10−5); no differences were observed between the nCR and VGPR groups (P = .2 and P = .9) or between these groups and the PR group (P = .1 and P = .8). A landmark study found a plateau phase in OS after 11 years; 35% patients in the CR group and 11% in the nCR+VGPR+PR group are alive at 17 years; 2 cases had relapsed in the nCR+VGPR+PR group. In conclusion, MM achieving CR after autologous stem cell transplantation is a central prognostic factor. The relapse rate is low in patients with > 11 years of follow-up, possibly signifying a cure for patients in CR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-01-332320

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 206

Metadata

Authors
Martinez-Lopez, J., Blade, J., Mateos, M.-V., Grande, C., Alegre, A., García-Laraña, J., Sureda, A., de la Rubia, J., Conde, E., Martinez, R., de Arriba, F., Viguria, M. C., Besalduch, J., Cabrera, R., Gonzalez-San Miguel, J. D., Guzman-Zamudio, J. L., Gomez del Castillo, M. C., Moraleda, J. M., García-Ruiz, J. C., San Miguel, J., Lahuerta, J. J., & Groups, F. T. G. (. E. D. M. A. P. (. P. E. E. D. L. T. E. H. M. C. S.
Venue
Blood
Published
2011-07-21
Volume
118
Issue
3
Pages
529-534
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1985021407
Cited by
206
References
4
FWCI
13.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. https://app.cochat.ai/papers/10.1182/blood-2011-01-332320
The paper
Martinez-Lopez, J., Blade, J., Mateos, M.-V., Grande, C., Alegre, A., García-Laraña, J., Sureda, A., de la Rubia, J., Conde, E., Martinez, R., de Arriba, F., Viguria, M. C., Besalduch, J., Cabrera, R., Gonzalez-San Miguel, J. D., Guzman-Zamudio, J. L., Gomez del Castillo, M. C., Moraleda, J. M., García-Ruiz, J. C., . . . Groups, F. T. G. (. E. D. M. A. P. (. P. E. E. D. L. T. E. H. M. C. S. (2011). Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. https://doi.org/10.1182/blood-2011-01-332320

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.